Bypassing the Blockade: RenovoRx Advances Pancreatic Cancer Treatment

MOUNTAIN VIEW, Calif. – October 01, 2026 – In the high-stakes arena of oncology, the most formidable barriers are often mechanical rather than purely biological. For decades, the dense, fibrous architecture of pancreatic tumors has acted as a fortress, repelling systemic treatments and leaving patients with few viable options. Today, a new publication adds significant weight to a localized approach that aims to breach these defenses directly.

RenovoRx, Inc., a commercial-stage clinical biopharmaceutical and medtech company, announced the publication of a peer-reviewed case series in Case Reports in Oncology. The study, conducted by researchers at Hackensack Meridian Health’s Jersey Shore University Medical Center, highlights the clinical potential of the company’s Trans-Arterial Micro-Perfusion (TAMP) delivery platform via its FDA-cleared RenovoCath device.

For a company navigating the turbulent waters of clinical-stage biotech, the independent validation provides a critical proof of concept. It also underscores a unique commercial strategy: generating early revenue through medical device sales while simultaneously pursuing a high-value drug-device combination approval in a notoriously difficult therapeutic space.

Navigating the Anatomical Blockade

Locally advanced pancreatic cancer (LAPC) presents one of the most daunting challenges in modern medicine. Survival benchmarks remain grim, with only about 23 percent of patients surviving one year post-diagnosis, a figure that plummets to 8.2 percent at the five-year mark. The primary hurdle in LAPC is not just the aggressive nature of the cancer cells, but the physical environment they construct.

Pancreatic tumors are characterized by a dense stroma—a thick, fibrous connective tissue that severely limits blood supply. Furthermore, these tumors frequently wrap around or invade critical nearby blood vessels, rendering them surgically inoperable.

Standard-of-care systemic chemotherapies, such as FOLFIRINOX or the combination of gemcitabine and nab-paclitaxel, struggle to penetrate this dense tissue in sufficient concentrations. Pushing higher doses through the bloodstream to overcome this barrier typically results in severe, often intolerable, systemic toxicity.

RenovoRx’s TAMP platform is designed to bypass this systemic blockade. Utilizing the RenovoCath device—a specialized double-balloon catheter—physicians can isolate the blood flow immediately adjacent to the tumor. Once isolated, the chemotherapy is infused directly across the arterial wall, essentially pressure-washing the tumor with the therapeutic agent.

Recent independent pharmacokinetic and pharmacodynamic sub-studies have demonstrated the mechanical efficiency of this approach. Data published earlier this year in Cancer Chemotherapy and Pharmacology indicated that TAMP-mediated delivery extracted approximately 51 percent of the drug locally at the tumor site, drastically reducing the amount of chemotherapy circulating through the rest of the patient’s body.

Real-World Clinical Validation

The newly published case series in Case Reports in Oncology moves this mechanical theory into real-world clinical practice. The study followed two patients with LAPC whose tumors were deemed completely unresectable due to complex blood vessel involvement, even after they had undergone extensive prior systemic treatments.

Both patients were treated with local intra-arterial gemcitabine delivered via the RenovoCath device. The results were notable: both individuals demonstrated a tangible tumor treatment response. This included significant reductions in CA 19-9, a primary biomarker used to monitor pancreatic cancer activity, and favorable imaging changes that showed a resolution of vascular narrowing. Crucially, these outcomes were achieved without major procedural complications.

“Locally advanced pancreatic cancer remains one of the most difficult cancers to treat, and patients have limited options when standard systemic therapies, like intravenous chemotherapy, are no longer effective,” said Gregory Tiesi, MD, FACS, FSSO, Chief of Surgical Oncology for the Southern Region and Medical Director of Hepatobiliary Surgery at Hackensack Meridian Health Jersey Shore University Medical Center, and lead author of the case series. “This case illustrates that gemcitabine can potentially be safely delivered at the local level via the TAMP platform in patients with complex vascular anatomy and adds to the peer-reviewed evidence supporting further utilization and evaluation of RenovoCath.”

The "Device First, Drug Later" Commercial Strategy

Beyond the clinical implications, RenovoRx’s current trajectory offers a fascinating case study in biotech corporate strategy. The traditional life sciences model often involves a decade of cash burn and dilutive capital raises while awaiting a pivotal Phase III binary event. RenovoRx has carved an alternative path.

Because the RenovoCath device received FDA 510(k) clearance in 2014 for the isolation of blood flow and delivery of fluids, the company has been able to commercialize the catheter as a standalone device while its Phase III drug-device trials run in the background.

This dual-pronged strategy is yielding tangible financial momentum. For its first full year of commercial efforts in 2025, RenovoRx generated approximately $1.1 million in RenovoCath sales. By the second quarter of 2026, the company reported record quarterly revenue of $909,000—a 61 percent sequential increase from the first quarter and a 115 percent jump year-over-year.

The financial architecture supporting this growth is equally robust, with gross margins holding steady at approximately 84 to 85 percent. Driven by this acceleration, the company recently raised and tightened its full-year 2026 revenue guidance to a range of $3.75 million to $4.25 million.

Market analysts tracking the medtech sector point out that this revenue is largely physician-driven. As of mid-2026, RenovoRx had secured 21 active commercial cancer center customers, including highly sought-after National Cancer Institute-designated centers. The technology is also beginning to cross indications, marked by the first commercial clinical use of RenovoCath in a sarcoma patient in August 2026.

The Path to 2027 and Phase III Readout

While the commercial device revenue provides a vital financial bridge and institutional footprint, the company's ultimate valuation catalyst remains the ongoing Phase III TIGeR-PaC trial.

This pivotal study is evaluating RenovoRx’s novel drug-device combination—intra-arterial gemcitabine (IAG) delivered via RenovoCath—against the current standard of care for LAPC. The trial is designed to measure overall survival, safety, and tolerability.

The regulatory framework surrounding IAG is highly favorable. The combination product has received Orphan Drug Designation (ODD) for both pancreatic cancer and bile duct cancer, which guarantees seven years of market exclusivity upon FDA approval. Furthermore, the company recently expanded its protective moat by securing an additional ODD for oxaliplatin in the treatment of pancreatic cancer.

RenovoRx achieved a major de-risking milestone in August 2026 by completing full patient enrollment for the TIGeR-PaC trial. The study is event-driven, requiring 86 patient events to conclude. With 78 events already recorded by mid-August, trial completion is firmly expected in the first half of 2027, setting the stage for a highly anticipated topline data readout in the second half of the year.

“Independent, peer-reviewed publications such as this case series provide important clinical evidence supporting the potential of our novel, targeted drug-delivery approach,” said Ramtin Agah, MD, RenovoRx’s Chief Medical Officer, Executive Chairman, and Founder. “These findings strengthen the scientific rationale for our drug-delivery platform and support our broader mission to bring meaningful new options to patients with difficult-to-treat tumors, especially as promising pancreatic treatments emerge that could be delivered via TAMP enabled by RenovoCath.”

As the oncology sector increasingly shifts toward precision and targeted therapies, the ability to physically maneuver therapeutics past anatomical blockades represents a critical frontier. With an expanding commercial footprint, validated real-world clinical data, and a fully enrolled Phase III trial, RenovoRx has positioned itself at the vanguard of this localized delivery movement, offering a strategic blueprint for how to build sustainable value while tackling one of medicine's most intractable diseases.